A Japanese conglomerate has found that the anti-parasitic drug ivermectin is effective and safe for the treatment of the coronavirus Omicron variant, according to a phase III clinical trial.
Kowa Co. Ltd., a conglomerate with interests in trading, hospitality, and electronics, along with health and medical applications, issued a press release (pdf) on Jan. 31 stating that ivermectin has been found to be effective against Omicron.
Kowa representatives didn’t immediately respond to a request for comment by The Epoch Times.
The company, working with Kitasato University based in Tokyo, said that ivermectin has the “same antiviral effect” on all “mutant strains,” including Alpha, Delta, and Omicron. Kowa added that ivermectin suppresses invasion of the virus and inhibits its replication.
“[Ivermectin] is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases,” the report said.
Ivermectin has been used by the World Health Organization for over 30 years to treat parasitic infections. Volunteers have distributed the drug in African countries where it has been found to be extremely effective, said the Kowa report.
However, the treatment has been mired in controversy during recent times as the U.S. Food and Drug Administration (FDA) has not approved the use of ivermectin as a treatment for COVID-19, even though the drug is used in humans to treat a variety of conditions.
FULL ARTICLE/COMMENTS"The federal government pays hospitals across the country to treat COVID-19 patients, but the payment is tied to approved methods, and ivermectin is not part of the protocol."
https://m.theepochtimes.com/ivermectin- ... 89uLL6ES9V